TOT Biopharm International Co (HKSE:01875) LT-Debt-to-Total-Asset : 0.22 (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TOT Biopharm International Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.22.

TOT Biopharm International Co's long-term debt to total assets ratio increased from Jun. 2023 (0.21) to Jun. 2024 (0.22). It may suggest that TOT Biopharm International Co is progressively becoming more dependent on debt to grow their business.

TOT Biopharm International Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for TOT Biopharm International Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TOT Biopharm International Co LT-Debt-to-Total-Asset Chart

TOT Biopharm International Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.09

0.17

0.21

0.22

TOT Biopharm International Co Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial									0.17	0.21	0.21	0.22	0.22

TOT Biopharm International Co LT-Debt-to-Total-Asset Calculation

TOT Biopharm International Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	331.283	/	1559.839
	=	0.21

TOT Biopharm International Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	339.156	/	1568.151
	=	0.22

TOT Biopharm International Co (HKSE:01875) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

TOT Biopharm International Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

TOT Biopharm International Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024

Website

https://www.totbiopharm.com.cn

TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China.

Executives

Center Laboratories, Inc.	2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited	2301 Trustee
Chengwei Evergreen Capital, Lp	2101 Beneficial owner
Center Laboratories Inc.	2101 Beneficial owner
Chengwei Evergreen Management, Llc	2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited	2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited

TOT Biopharm International Co Headlines

No Headlines